Distribution · MENA · Announced 12 Nov 2026

Emmaus Life Sciences → Al Wataniya Aldawliya

Emmaus Life Sciences signed an exclusive distribution agreement with Al Wataniya Aldawliya, part of ACMEM, to bring its sickle cell disease therapy Endari to Libya, its first commercial presence in North Africa.

Parties: Emmaus Life Sciences (United States) → Al Wataniya Aldawliya (ACMEM)

Deal type
Distribution
Value
Undisclosed
Territory
Libya (exclusive distribution); separate real-world evidence work in UAE, Oman, Bahrain, Kuwait and Saudi Arabia
Therapeutic area
Rare / Orphan
Asset
Endari (L-glutamine)
Announced
12 Nov 2026

Our analysis

Why this matters

Emmaus Life Sciences announced on 12 November 2026 an exclusive distribution agreement with Al Wataniya Aldawliya, a member of Assada Company for Medical Equipment and Medicine (ACMEM), for Endari (L-glutamine oral powder) in Libya. The partner will support participation in Ministry of Health tenders and site registration. Financial terms, contract length and launch timing were not disclosed.

The same announcement described two real-world evidence programmes in the Gulf: an ongoing observational study of up to 240 sickle cell patients across the UAE, Oman, Bahrain and Kuwait, and outcomes-data work at Saudi military healthcare institutions, both running for about two years. Endari already holds marketing authorisations in the UAE, Qatar, Kuwait, Bahrain and Oman.

The full analysis is free to read with a work email on this page.

Source: Business Wire (Emmaus Life Sciences press release)

Latest deals

All MENA deals → · All distribution deals → · Browse all emerging-market pharma deals →